- Home
- WINT vs LIPO Comparison
WINT vs LIPO Comparison
Compare WINT & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- LIPO
- Stock Information
- Founded
- WINT 1992
- LIPO 2005
- Country
- WINT United States
- LIPO United States
- Employees
- WINT N/A
- LIPO N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- LIPO Health Care
- Exchange
- WINT Nasdaq
- LIPO Nasdaq
- Market Cap
- WINT 3.6M
- LIPO 3.1M
- IPO Year
- WINT 1995
- LIPO 2022
- Fundamental
- Price
- WINT $0.57
- LIPO $2.99
- Analyst Decision
- WINT Hold
- LIPO
- Analyst Count
- WINT 1
- LIPO 0
- Target Price
- WINT $350.00
- LIPO N/A
- AVG Volume (30 Days)
- WINT 264.4K
- LIPO 39.2K
- Earning Date
- WINT 05-16-2025
- LIPO 05-14-2025
- Dividend Yield
- WINT N/A
- LIPO N/A
- EPS Growth
- WINT N/A
- LIPO N/A
- EPS
- WINT N/A
- LIPO N/A
- Revenue
- WINT N/A
- LIPO $519,866.00
- Revenue This Year
- WINT N/A
- LIPO N/A
- Revenue Next Year
- WINT N/A
- LIPO N/A
- P/E Ratio
- WINT N/A
- LIPO N/A
- Revenue Growth
- WINT N/A
- LIPO 8.88
- 52 Week Low
- WINT $0.55
- LIPO $1.97
- 52 Week High
- WINT $737.44
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- WINT 26.04
- LIPO 58.50
- Support Level
- WINT $0.67
- LIPO $2.75
- Resistance Level
- WINT $0.81
- LIPO $3.17
- Average True Range (ATR)
- WINT 0.06
- LIPO 0.29
- MACD
- WINT 0.01
- LIPO 0.02
- Stochastic Oscillator
- WINT 5.24
- LIPO 81.05
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.